Annual survey results reveal company receives top ranking in community setting for the fifth consecutive year
CHICAGO–(BUSINESS WIRE)–$MDRX #HealthIT–Allscripts (NASDAQ: MDRX) has been recognized as the top-rated electronic health record vendor for community hospitals according to new survey results from Black Book Research. This is the fifth consecutive year Allscripts has earned the top rating in this annual survey.
The survey features responses collected from more than 1,800 community hospitals and focuses on 18 key performance indicators. Approximately 50% of the responses came from nurses, physicians, and other direct users of the technology being surveyed, while additional responses came from CEOs, CFOs, trustees and operational leaders. Survey responses were collected between the third quarter of 2020 and the first quarter of 2021.
Allscripts ranked first in 10 of 18 key performance indicators, including:
“Allscripts’ heightened focus on the community hospital market is evident based on the positive results from this year’s survey, which for the fifth year in a row resulted in the number-one rating amongst the eight top EHR vendors evaluated,” said Doug Brown, Managing Partner and President, Black Book.
“Today’s community hospitals are challenged with increased complexity in healthcare delivery, limited resources and rising operating costs,” said Paul Black, Allscripts Chief Executive Officer. “Black Book’s comprehensive survey shows Allscripts’ commitment to providing smaller healthcare organizations with the support, cloud technology and tools they need. We are honored to serve as our clients’ trusted partner, delivering innovative solutions that meet community-hospital goals, as we share their mission to provide superior patient care.”
Black Book Research is a full-service healthcare-centric market research and public opinion research company and premier provider of competitive intelligence, market research, opinion mining, sentiment analysis, services evaluation and strategic consulting services to companies worldwide. To ensure survey integrity and accurate, comprehensive results, Black Book’s comprehensive methodology is crowd-sourced and represents a broad spectrum of solution users. Survey responses go through both internal and external audits, ensuring completeness, accuracy and validity. For more information, visit www.blackbookmarketresearch.com.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2021 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
Contacts
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com
Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com
KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or…
STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF)…
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company…
Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif.,…
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI…
July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved…